Wong Albert H C, Van Tol Hubert H M
Laboratory of Molecular Neurobiology, Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, Canada M5T 1R8.
Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1091-9. doi: 10.1016/j.pnpbp.2003.09.005.
The dopamine D4 receptor (D4) is a target for most common neuroleptic medications. After its initial discovery, it was found to possess the highest affinity of all dopamine receptor subtypes for the archetypical, atypical, antipsychotic clozapine. Nevertheless, initial clinical trials have not provided evidence that this receptor is a primary target for antipsychotic drugs. Considering the accumulated in vivo evidence that at least a subgroup of psychotic patients have altered dopamine signaling, all dopamine receptor subtypes likely contribute to the phenotypic expression of schizophrenia. New insights into the function of this receptor and its role in the modulation of excitatory signaling support the view that this dopamine receptor may affect attention and cognition. In this review, the authors outline some recent developments that provide insight into D4 receptor physiology, function and its possible relationship to schizophrenia treatment.
多巴胺D4受体(D4)是大多数常见抗精神病药物的作用靶点。在其最初被发现后,人们发现它对典型和非典型抗精神病药物氯氮平具有所有多巴胺受体亚型中最高的亲和力。然而,最初的临床试验并未提供证据表明该受体是抗精神病药物的主要靶点。鉴于积累的体内证据表明至少有一部分精神病患者存在多巴胺信号改变,所有多巴胺受体亚型可能都参与了精神分裂症的表型表达。对该受体功能及其在兴奋性信号调节中作用的新见解支持了这样一种观点,即这种多巴胺受体可能影响注意力和认知。在这篇综述中,作者概述了一些近期的进展,这些进展有助于深入了解D4受体的生理学、功能及其与精神分裂症治疗可能的关系。